BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res 2020;126:1260-80. [PMID: 32324502 DOI: 10.1161/CIRCRESAHA.120.315937] [Cited by in Crossref: 205] [Cited by in F6Publishing: 211] [Article Influence: 68.3] [Reference Citation Analysis]
Number Citing Articles
1 Liao Y, Fu Z, Huang Y, Wu S, Wang Z, Ye S, Zeng W, Zeng G, Li D, Yang Y, Pei K, Yang J, Hu Z, Liang X, Hu J, Liu M, Jin J, Cai C. Interleukin-18-primed human umbilical cord-mesenchymal stem cells achieve superior therapeutic efficacy for severe viral pneumonia via enhancing T-cell immunosuppression. Cell Death Dis 2023;14:66. [PMID: 36707501 DOI: 10.1038/s41419-023-05597-3] [Reference Citation Analysis]
2 Palazzuoli A, Tramonte F, Beltrami M. Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature. Biomolecules 2023;13. [PMID: 36671558 DOI: 10.3390/biom13010173] [Reference Citation Analysis]
3 Perrone MA, Aimo A, Bernardini S, Clerico A. Inflammageing and Cardiovascular System: Focus on Cardiokines and Cardiac-Specific Biomarkers. Int J Mol Sci 2023;24. [PMID: 36614282 DOI: 10.3390/ijms24010844] [Reference Citation Analysis]
4 Toldo S, Mezzaroma E, Potere N, Mauro AG, Kron J, Salloum FN, Abbate A. The inflammasome in cardiovascular diseases. Inflammasome Biology 2023. [DOI: 10.1016/b978-0-323-91802-2.00024-4] [Reference Citation Analysis]
5 Guo X, Ma L. Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors. Coron Artery Dis 2023;34:66-77. [PMID: 36317383 DOI: 10.1097/MCA.0000000000001198] [Reference Citation Analysis]
6 Zhao Z, Pan Z, Zhang S, Ma G, Zhang W, Song J, Wang Y, Kong L, Du G. Neutrophil extracellular traps: A novel target for the treatment of stroke. Pharmacol Ther 2023;241:108328. [PMID: 36481433 DOI: 10.1016/j.pharmthera.2022.108328] [Reference Citation Analysis]
7 Coll RC. Therapeutic targeting of inflammasome signaling by blocking interleukin-1. Inflammasome Biology 2023. [DOI: 10.1016/b978-0-323-91802-2.00010-4] [Reference Citation Analysis]
8 Ramos-Martinez E, Vega-Sánchez AE, Pérez-Rubio G, Mejia M, Buendía-Roldán I, González-Pérez MI, Mateos-Toledo HN, Andrade WA, Falfán-Valencia R, Rojas-Serrano J. Enhanced Activity of NLRP3 Inflammasome in the Lung of Patients with Anti-Synthetase Syndrome. Cells 2022;12. [PMID: 36611853 DOI: 10.3390/cells12010060] [Reference Citation Analysis]
9 Giambelluca S, Ochs M, Lopez-Rodriguez E. Resting time after phorbol 12-myristate 13-acetate in THP-1 derived macrophages provides a non-biased model for the study of NLRP3 inflammasome. Front Immunol 2022;13:958098. [PMID: 36618426 DOI: 10.3389/fimmu.2022.958098] [Reference Citation Analysis]
10 González L, Rivera K, Andia ME, Martínez Rodriguez G. The IL-1 Family and Its Role in Atherosclerosis. Int J Mol Sci 2022;24. [PMID: 36613465 DOI: 10.3390/ijms24010017] [Reference Citation Analysis]
11 Chen Y, Luo X, Xu B, Bao X, Jia H, Yu B. Oxidative Stress-Mediated Programmed Cell Death: a Potential Therapy Target for Atherosclerosis. Cardiovasc Drugs Ther 2022. [DOI: 10.1007/s10557-022-07414-z] [Reference Citation Analysis]
12 Yang L, Zhang X, Wang Q. Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis. Front Endocrinol (Lausanne) 2022;13:992937. [PMID: 36589841 DOI: 10.3389/fendo.2022.992937] [Reference Citation Analysis]
13 Tsioufis P, Theofilis P, Tsioufis K, Tousoulis D. The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches. Int J Mol Sci 2022;23. [PMID: 36555579 DOI: 10.3390/ijms232415937] [Reference Citation Analysis]
14 Ng SSW, Dawson LA. Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma. Biomedicines 2022;10. [PMID: 36551971 DOI: 10.3390/biomedicines10123215] [Reference Citation Analysis]
15 Yu Z, Fidler TP, Ruan Y, Vlasschaert C, Nakao T, Uddin MM, Mack T, Niroula A, Heimlich JB, Zekavat SM, Gibson CJ, Griffin GK, Wang Y, Peloso GM, Heard-costa N, Levy D, Vasan RS, Aguet F, Ardlie K, Taylor KD, Rich SS, Rotter JI, Libby P, Jaiswal S, Ebert BL, Bick AG, Tall AR, Natarajan P. Genetic modification of inflammation and clonal hematopoiesis-associated coronary artery disease.. [DOI: 10.1101/2022.12.08.22283237] [Reference Citation Analysis]
16 Mo DG, Wang L, Han QF, Yu K, Liu JH, Yao HC. NLRP3 Inflammasome May Be a Biomarker for Risk Stratification in Patients with Acute Coronary Syndrome. J Inflamm Res 2022;15:6595-605. [PMID: 36510493 DOI: 10.2147/JIR.S383903] [Reference Citation Analysis]
17 Lin T, Hu L, Hu F, Li K, Wang CY, Zong LJ, Zhao YQ, Zhang X, Li Y, Yang Y, Wang Y, Jiang CY, Wu X, Liu WT. NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy. Cancer Immunol Res 2022;10:1542-58. [PMID: 36255412 DOI: 10.1158/2326-6066.CIR-22-0197] [Reference Citation Analysis]
18 Chen X, Chen Y, Ou Y, Min W, Liang S, Hua L, Zhou Y, Zhang C, Chen P, Yang Z, Hu W, Sun P. Bortezomib inhibits NLRP3 inflammasome activation and NF-κB pathway to reduce psoriatic inflammation. Biochemical Pharmacology 2022;206:115326. [DOI: 10.1016/j.bcp.2022.115326] [Reference Citation Analysis]
19 Wu Z, Luo C, Zheng B. Progress of Research into the Interleukin-1 Family in Cardiovascular Disease. JIR 2022;Volume 15:6683-6694. [DOI: 10.2147/jir.s390915] [Reference Citation Analysis]
20 Thapa P, Upadhyay SP, Singh V, Boinpelly VC, Zhou J, Johnson DK, Gurung P, Lee ES, Sharma R, Sharma M. Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors. European Journal of Medicinal Chemistry Reports 2022. [DOI: 10.1016/j.ejmcr.2022.100100] [Reference Citation Analysis]
21 Alieva AM, Kislyakov VA, Voronkova KV, Reznik EV, Arakelyan RA, Saryev MN, Valiev RK, Rakhaev AM, Hasanova ET, Kalova MR, Nikitin IG. Interleukin-1 is a Biological Marker in Heart Failure. Arhivʺ vnutrennej mediciny 2022;12:422-429. [DOI: 10.20514/2226-6704-2022-12-6-422-429] [Reference Citation Analysis]
22 Baritussio A, Cheng CY, Lorenzoni G, Basso C, Rizzo S, De Gaspari M, Fachin F, Giordani AS, Ocagli H, Pontara E, Cattini MGP, Bison E, Gallo N, Plebani M, Tarantini G, Iliceto S, Gregori D, Marcolongo R, Caforio ALP. A Machine-Learning Model for the Prognostic Role of C-Reactive Protein in Myocarditis. J Clin Med 2022;11. [PMID: 36498643 DOI: 10.3390/jcm11237068] [Reference Citation Analysis]
23 Yi Y. MicroRNA-mediated epigenetic regulation of inflammasomes in inflammatory responses and immunopathologies. Seminars in Cell & Developmental Biology 2022. [DOI: 10.1016/j.semcdb.2022.11.006] [Reference Citation Analysis]
24 Shi Y, Zhao L, Wang J, Liu S, Zhang Y, Qin Q. The selective NLRP3 inflammasome inhibitor MCC950 improves isoproterenol-induced cardiac dysfunction by inhibiting cardiomyocyte senescence. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175364] [Reference Citation Analysis]
25 Xie M, Wang H, Peng J, Qing D, Zhang X, Guo D, Meng P, Luo Z, Wang X, Peng Q. Acacetin protects against depression-associated dry eye disease by regulating ubiquitination of NLRP3 through gp78 signal. Front Pharmacol 2022;13:984475. [DOI: 10.3389/fphar.2022.984475] [Reference Citation Analysis]
26 Potere N, Del Buono MG, Caricchio R, Cremer PC, Vecchié A, Porreca E, Dalla Gasperina D, Dentali F, Abbate A, Bonaventura A. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications. EBioMedicine 2022;85:104299. [PMID: 36209522 DOI: 10.1016/j.ebiom.2022.104299] [Reference Citation Analysis]
27 Bretheau F, Castellanos-Molina A, Bélanger D, Kusik M, Mailhot B, Boisvert A, Vallières N, Lessard M, Gunzer M, Liu X, Boilard É, Quan N, Lacroix S. The alarmin interleukin-1α triggers secondary degeneration through reactive astrocytes and endothelium after spinal cord injury. Nat Commun 2022;13:5786. [PMID: 36184639 DOI: 10.1038/s41467-022-33463-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Billingsley HE, Del Buono MG, Canada JM, Kim Y, Damonte JI, Trankle CR, Halasz G, Mihalick V, Vecchié A, Markley RR, Kadariya D, Bressi E, Medina de Chazal H, Chiabrando JG, Mbualungu J, Turlington J, Arena R, Van Tassell BW, Abbate A, Carbone S. Sarcopenic Obesity Is Associated With Reduced Cardiorespiratory Fitness Compared With Nonsarcopenic Obesity in Patients With Heart Failure With Reduced Ejection Fraction. Circ Heart Fail 2022;15:e009518. [PMID: 36098058 DOI: 10.1161/CIRCHEARTFAILURE.122.009518] [Reference Citation Analysis]
29 Sun J, Li Y. Pyroptosis and respiratory diseases: A review of current knowledge. Front Immunol 2022;13:920464. [DOI: 10.3389/fimmu.2022.920464] [Reference Citation Analysis]
30 Zhou W, Wang C, Liu Z, Gou S. Hypoxia-Activated Prodrugs with Dual COX-2/CA Inhibitory Effects on Attenuating Cardiac Inflammation under Hypoxia. J Med Chem 2022. [PMID: 36170566 DOI: 10.1021/acs.jmedchem.2c01355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Alhajri N, Rustom M, Adegbile A, Ahmed W, Kilidar S, Afify N. Deciphering the Basis of Molecular Biology of Selected Cardiovascular Diseases: A View on Network Medicine. IJMS 2022;23:11421. [DOI: 10.3390/ijms231911421] [Reference Citation Analysis]
32 Al-Kuraishy HM, Al-Fakhrany OM, Elekhnawy E, Al-Gareeb AI, Alorabi M, De Waard M, Albogami SM, Batiha GE. Traditional herbs against COVID-19: back to old weapons to combat the new pandemic. Eur J Med Res 2022;27:186. [PMID: 36154838 DOI: 10.1186/s40001-022-00818-5] [Reference Citation Analysis]
33 Wang B, Sun T, Sun L, Li L, Wan H, Ding Z, Ye X. Amygdalin attenuates PM2.5-induced human umbilical vein endothelial cell injury via the TLR4/NF-κB and Bcl-2/Bax signaling pathways. Acta Biochim Biophys Sin (Shanghai) 2022;54:1476-85. [PMID: 36178164 DOI: 10.3724/abbs.2022136] [Reference Citation Analysis]
34 Zeng L, Lin Z, Kang P, Zhang M, Tang H, Li M, Xu K, Liu Y, Jiang Z, Huo S. Identification of Interleukin-1-Beta Inhibitors in Gouty Arthritis Using an Integrated Approach Based on Network Pharmacology, Molecular Docking, and Cell Experiments. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-18. [DOI: 10.1155/2022/2322417] [Reference Citation Analysis]
35 Pan Y, Cai W, Huang J, Cheng A, Wang M, Yin Z, Jia R. Pyroptosis in development, inflammation and disease. Front Immunol 2022;13:991044. [DOI: 10.3389/fimmu.2022.991044] [Reference Citation Analysis]
36 Dobrev D, Heijman J, Hiram R, Li N, Nattel S. Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology. Nat Rev Cardiol. [DOI: 10.1038/s41569-022-00759-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Chen M, Meng X, Han Y, Yan J, Xiao C, Qian L. Profile of crosstalk between glucose and lipid metabolic disturbance and diabetic cardiomyopathy: Inflammation and oxidative stress. Front Endocrinol 2022;13:983713. [DOI: 10.3389/fendo.2022.983713] [Reference Citation Analysis]
38 Cai C, Liao Y, Fu Z, Huang Y, Wu S, Wang Z, Ye S, Zeng W, Zeng G, Li D, Yang Y, Pei K, Yang J, Hu Z, Liang X, Hu J, Liu M. Interleukin-18-primed human umbilical cord-mesenchymal stem cells achieve superior therapeutic efficacy for severe viral pneumonia via enhancing T-cell immunosuppression.. [DOI: 10.21203/rs.3.rs-2012946/v1] [Reference Citation Analysis]
39 Ding K, Song C, Hu H, Yin K, Huang H, Tang H, Jakovljevic V. The Role of NLRP3 Inflammasome in Diabetic Cardiomyopathy and Its Therapeutic Implications. Oxidative Medicine and Cellular Longevity 2022;2022:1-19. [DOI: 10.1155/2022/3790721] [Reference Citation Analysis]
40 Speer T, Dimmeler S, Schunk SJ, Fliser D, Ridker PM. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nat Rev Nephrol 2022. [PMID: 36064794 DOI: 10.1038/s41581-022-00621-9] [Reference Citation Analysis]
41 Huang L, Kuo C, Tseng L, Li Y, Cheng L, Cheng C, Sheu S, Chang W, Chen C, Cheng H. Alpha-Mangostin Reduces Pericellular Fibronectin on Suspended Tumor Cells and Therapeutically, but Not Prophylactically, Suppresses Distant Metastasis. Life 2022;12:1375. [DOI: 10.3390/life12091375] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Asgharifar SF, Heris MJ. Role of the NLRP3-Q705K polymorphism in the pathogenesis of inflammatory-mediated diseases: A brief look at impacts of the Q705 polymorphism and NLRP3 activation on cancer immunotherapy. Human Gene 2022;33:201057. [DOI: 10.1016/j.humgen.2022.201057] [Reference Citation Analysis]
43 Genetzakis E, Gilchrist J, Kassiou M, Figtree GA. Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease? Pharmacology & Therapeutics 2022;237:108228. [DOI: 10.1016/j.pharmthera.2022.108228] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Zhang L, Li W, Shi B, Zhang X, Gong K. Expression profiles and functions of ferroptosis-related genes in intimal hyperplasia induced by carotid artery ligation in mice. Front Genet 2022;13:964458. [DOI: 10.3389/fgene.2022.964458] [Reference Citation Analysis]
45 Chen Y, Chen X, Liang S, Ou Y, Lin G, Hua L, Wu X, Zhou Y, Liu Z, Cai H, Yang Z, Hu W, Sun P. Chlorquinaldol inhibits the activation of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 inflammasome and ameliorates imiquimod-induced psoriasis-like dermatitis in mice. Chem Biol Interact 2022;365:110122. [PMID: 36002070 DOI: 10.1016/j.cbi.2022.110122] [Reference Citation Analysis]
46 Del Buono MG, Moroni F, Montone RA, Azzalini L, Sanna T, Abbate A. Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction. Curr Cardiol Rep 2022. [PMID: 35972638 DOI: 10.1007/s11886-022-01766-6] [Reference Citation Analysis]
47 Almeida-Santiago C, Quevedo-Abeledo JC, Hernández-Hernández V, de Vera-González A, Gonzalez-Delgado A, González-Gay MÁ, Ferraz-Amaro I. Interleukin 1 receptor antagonist relation to cardiovascular disease risk in patients with rheumatoid arthritis. Sci Rep 2022;12:13698. [PMID: 35953706 DOI: 10.1038/s41598-022-18128-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Shao BZ, Xu HY, Zhao YC, Zheng XR, Wang F, Zhao GR. NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation. Inflammation 2022. [PMID: 35953687 DOI: 10.1007/s10753-022-01725-x] [Reference Citation Analysis]
49 Wang Y, Wang Q, Xu D. New insights into macrophage subsets in atherosclerosis. J Mol Med (Berl) 2022. [PMID: 35930063 DOI: 10.1007/s00109-022-02224-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Gilpin TR, Mahmoudi M. Pericardial disease. Medicine 2022. [DOI: 10.1016/j.mpmed.2022.06.006] [Reference Citation Analysis]
51 Sun C, Zhao H, Han Y, Wang Y, Sun X. The Role of Inflammasomes in COVID-19: Potential Therapeutic Targets. J Interferon Cytokine Res 2022;42:406-20. [PMID: 35984324 DOI: 10.1089/jir.2022.0061] [Reference Citation Analysis]
52 Espitia-Corredor JA, Boza P, Espinoza-Pérez C, Lillo JM, Rimassa-Taré C, Machuca V, Osorio-Sandoval JM, Vivar R, Bolivar S, Pardo-Jiménez V, Sánchez-Ferrer CF, Peiró C, Díaz-Araya G. Angiotensin II Triggers NLRP3 Inflammasome Activation by a Ca2+ Signaling-Dependent Pathway in Rat Cardiac Fibroblast Ang-II by a Ca2+-Dependent Mechanism Triggers NLRP3 Inflammasome in CF. Inflammation 2022. [PMID: 35867264 DOI: 10.1007/s10753-022-01707-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Elrakaybi A, Laubner K, Zhou Q, Hug MJ, Seufert J. Cardiovascular protection by SGLT2 inhibitors - Do anti-inflammatory mechanisms play a role? Mol Metab 2022;:101549. [PMID: 35863639 DOI: 10.1016/j.molmet.2022.101549] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Lara-Reyna S, Caseley EA, Topping J, Rodrigues F, Jimenez Macias J, Lawler SE, McDermott MF. Inflammasome activation: from molecular mechanisms to autoinflammation. Clin Transl Immunology 2022;11:e1404. [PMID: 35832835 DOI: 10.1002/cti2.1404] [Reference Citation Analysis]
55 Read DF, Booth GT, Daza RM, Jackson DL, Gladden RG, Srivatsan SR, Ewing B, Franks JM, Spurrell CH, Gomes AR, O’day D, Gogate AA, Martin BK, Starita L, Lin Y, Shendure J, Lin S, Trapnell C. Single-cell analysis of chromatin and expression reveals age- and sex-associated alterations in the human heart.. [DOI: 10.1101/2022.07.12.496461] [Reference Citation Analysis]
56 Long Q, Li L, Yang H, Lu Y, Yang H, Zhu Y, Tang Y, Liu C, Yuan J. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol 2022;110:109024. [PMID: 35841866 DOI: 10.1016/j.intimp.2022.109024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Guo X, Chen H, Zhou Y, Shen L, Wu S, Chen Y. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. Expert Opin Investig Drugs 2022;:1-12. [PMID: 35786092 DOI: 10.1080/13543784.2022.2097067] [Reference Citation Analysis]
58 Li M, Wang J, Qian Q, Chen B, Zhang Z, Zhang Y, Hall DD, Abel ED, Song L, Yang L. Gamma-interferon-inducible lysosomal thiol reductase maintains cardiac immuno-metabolic homeostasis in heart failure.. [DOI: 10.1101/2022.07.03.498477] [Reference Citation Analysis]
59 Mandell JT, de Rivero Vaccari JP, Sabater AL, Galor A. The inflammasome pathway: A key player in ocular surface and anterior segment diseases. Surv Ophthalmol 2022:S0039-6257(22)00087-X. [PMID: 35798189 DOI: 10.1016/j.survophthal.2022.06.003] [Reference Citation Analysis]
60 Mihalick V, Wohlford G, Talasaz AH, Ho AJ, Kim F, Canada JM, Carbone S, Kadariya D, Billingsley H, Trankle C, Del Buono MG, Moroni F, Arena R, Abbate A, Van Tassell B. Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure. Am J Cardiol 2022;174:61-7. [PMID: 35473780 DOI: 10.1016/j.amjcard.2022.03.026] [Reference Citation Analysis]
61 He L, Zhang CL, Chen Q, Wang L, Huang Y. Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics. Pharmacol Ther 2022;235:108152. [PMID: 35122834 DOI: 10.1016/j.pharmthera.2022.108152] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
62 Makaremi S, Asgarzadeh A, Kianfar H, Mohammadnia A, Asghariazar V, Safarzadeh E. The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19. Inflamm Res 2022. [PMID: 35751653 DOI: 10.1007/s00011-022-01596-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Bayes-genis A, Cediel G, Domingo M, Codina P, Santiago E, Lupón J. Biomarkers in Heart Failure with Preserved Ejection Fraction. Card Fail Rev 2022;8:e20. [DOI: 10.15420/cfr.2021.37] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Stojanovic D, Mitic V, Stojanovic M, Milenkovic J, Ignjatovic A, Milojkovic M. The Scientific Rationale for the Introduction of Renalase in the Concept of Cardiac Fibrosis. Front Cardiovasc Med 2022;9:845878. [PMID: 35711341 DOI: 10.3389/fcvm.2022.845878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Van Tassell B, Mihalick V, Thomas G, Marawan A, Talasaz AH, Lu J, Kang L, Ladd A, Damonte JI, Dixon DL, Markley R, Turlington J, Federmann E, Del Buono MG, Biondi-Zoccai G, Canada JM, Arena R, Abbate A. Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study. J Transl Med 2022;20:270. [PMID: 35706006 DOI: 10.1186/s12967-022-03466-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Wang Y, Li Y, Zhang W, Yuan Z, Lv S, Zhang J. NLRP3 Inflammasome: a Novel Insight into Heart Failure. J Cardiovasc Transl Res 2022. [PMID: 35697978 DOI: 10.1007/s12265-022-10286-1] [Reference Citation Analysis]
67 Li X, Zhang Z, Wang Z, Gutiérrez-Castrellón P, Shi H. Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. Signal Transduct Target Ther 2022;7:186. [PMID: 35697684 DOI: 10.1038/s41392-022-01043-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
68 Mueller PA, Yerkes E, Bergstrom P, Rosario S, Hay J, Pamir N. A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research. Sci Rep 2022;12:9138. [PMID: 35650291 DOI: 10.1038/s41598-022-13040-4] [Reference Citation Analysis]
69 Cen X, Wang B, Liang Y, Chen Y, Xiao Y, Du S, Nandakumar KS, Yin H, Liu S, Cheng K. Small molecule SMU-CX24 targeting Toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.06.001] [Reference Citation Analysis]
70 Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian Sorbeni F, Farahzadi R, Ghasemnejad T. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J 2022;19:92. [PMID: 35619180 DOI: 10.1186/s12985-022-01814-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
71 Cui Y, Yu H, Bu Z, Wen L, Yan L, Feng J. Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics. Front Mol Neurosci 2022;15:894298. [DOI: 10.3389/fnmol.2022.894298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 González-candia A, Candia AA, Paz A, Mobarec F, Urbina-varela R, Campo AD, Herrera EA, Castillo RL. Cardioprotective Antioxidant and Anti-Inflammatory Mechanisms Induced by Intermittent Hypobaric Hypoxia. Antioxidants 2022;11:1043. [DOI: 10.3390/antiox11061043] [Reference Citation Analysis]
73 Alloatti G, Penna C, Comità S, Tullio F, Aragno M, Biasi F, Pagliaro P. Aging, sex and NLRP3 inflammasome in cardiac ischaemic disease. Vascul Pharmacol 2022;:107001. [PMID: 35623548 DOI: 10.1016/j.vph.2022.107001] [Reference Citation Analysis]
74 Feijóo-Bandín S, Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, González-Juanatey JR, Lago F. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Int J Mol Sci 2022;23:5634. [PMID: 35628443 DOI: 10.3390/ijms23105634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Haryono A, Ramadhiani R, Ryanto GRT, Emoto N. Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going. Biology (Basel) 2022;11:759. [PMID: 35625487 DOI: 10.3390/biology11050759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Wang M, Zhao M, Yu J, Xu Y, Zhang J, Liu J, Zheng Z, Ye J, Wang Z, Ye D, Feng Y, Xu S, Pan W, Wei C, Wan J. MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice. Front Cardiovasc Med 2022;9:727474. [DOI: 10.3389/fcvm.2022.727474] [Reference Citation Analysis]
77 Walkowski B, Kleibert M, Majka M, Wojciechowska M. Insight into the Role of the PI3K/Akt Pathway in Ischemic Injury and Post-Infarct Left Ventricular Remodeling in Normal and Diabetic Heart. Cells 2022;11:1553. [DOI: 10.3390/cells11091553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
78 Yuan JY, Fu Y, Feng ZH, Sang F, Shao MY, Li LL. Potential Mechanisms and Effects of Chinese Medicines in Treatment of Diabetic Atherosclerosis by Modulating NLRP3 Inflammasome: A Narrative Review. Chin J Integr Med 2022. [PMID: 35507299 DOI: 10.1007/s11655-022-3513-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Rong W, Liu C, Li X, Wan N, Wei L, Zhu W, Bai P, Li M, Ou Y, Li F, Wang L, Wu X, Liu J, Xing M, Zhao X, Liu H, Zhang H, Lyu A. Caspase-8 Promotes Pulmonary Hypertension by Activating Macrophage-Associated Inflammation and IL-1β (Interleukin 1β) Production. Arterioscler Thromb Vasc Biol 2022;42:613-31. [PMID: 35387479 DOI: 10.1161/ATVBAHA.121.317168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Ku EJ, Kim BR, Lee JI, Lee YK, Oh TJ, Jang HC, Choi SH. The Anti-Atherosclerosis Effect of Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Apolipoprotein E Knockout Mice. Int J Mol Sci 2022;23:4906. [PMID: 35563294 DOI: 10.3390/ijms23094906] [Reference Citation Analysis]
81 von Ehr A, Bode C, Hilgendorf I. Macrophages in Atheromatous Plaque Developmental Stages. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.865367] [Reference Citation Analysis]
82 Pilard M, Ollivier EL, Gourdou-latyszenok V, Couturaud F, Lemarié CA. Endothelial Cell Phenotype, a Major Determinant of Venous Thrombo-Inflammation. Front Cardiovasc Med 2022;9:864735. [DOI: 10.3389/fcvm.2022.864735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Bielas H, Meister-Langraf RE, Schmid JP, Barth J, Znoj H, Schnyder U, Princip M, von Känel R. Relationship between a Self-Reported History of Depression and Persistent Elevation in C-Reactive Protein after Myocardial Infarction. J Clin Med 2022;11:2322. [PMID: 35566447 DOI: 10.3390/jcm11092322] [Reference Citation Analysis]
84 Buono MGD, Garmendia CM, Seropian IM, Gonzalez G, Berrocal DH, Biondi-Zoccai G, Trankle CR, Bucciarelli-Ducci C, Thiele H, Lavie CJ, Crea F, Abbate A. Heart Failure After ST-Elevation Myocardial Infarction: Beyond Left Ventricular Adverse Remodeling. Curr Probl Cardiol 2022;:101215. [PMID: 35460680 DOI: 10.1016/j.cpcardiol.2022.101215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Imazio M, Abbate A. The inflammasome as a therapeutic target for myopericardial diseases. Minerva Cardiol Angiol 2022;70:238-47. [PMID: 35412034 DOI: 10.23736/S2724-5683.21.05876-2] [Reference Citation Analysis]
86 Tang YQ, Li ZW, Feng YF, Yang HQ, Hou CL, Geng C, Yang PR, Zhao HM, Wang J. MK2206 attenuates atherosclerosis by inhibiting lipid accumulation, cell migration, proliferation, and inflammation. Acta Pharmacol Sin 2022;43:897-907. [PMID: 34316032 DOI: 10.1038/s41401-021-00729-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
87 Moise N, Friedman A. A mathematical model of immunomodulatory treatment in myocardial infarction. Journal of Theoretical Biology 2022. [DOI: 10.1016/j.jtbi.2022.111122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Wang S, Hu S, Luo X, Bao X, Li J, Liu M, Lv Y, Zhao C, Zeng M, Chen X, Unsworth A, Jones S, Johnson TW, White SJ, Jia H, Yu B. Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. eBioMedicine 2022;78:103964. [DOI: 10.1016/j.ebiom.2022.103964] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Diab A, Valenzuela Ripoll C, Guo Z, Javaheri A. HDL Composition, Heart Failure, and Its Comorbidities. Front Cardiovasc Med 2022;9:846990. [PMID: 35350538 DOI: 10.3389/fcvm.2022.846990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
90 Wang J, Chen P, Cao Q, Wang W, Chang X, Li T. Traditional Chinese Medicine Ginseng Dingzhi Decoction Ameliorates Myocardial Fibrosis and High Glucose-Induced Cardiomyocyte Injury by Regulating Intestinal Flora and Mitochondrial Dysfunction. Oxidative Medicine and Cellular Longevity 2022;2022:1-33. [DOI: 10.1155/2022/9205908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
91 Vecchié A, Del Buono MG, Mauro AG, Cremer PC, Imazio M, Klein AL, Abbate A, Dentali F, Bonaventura A. Advances in pharmacotherapy for acute and recurrent pericarditis. Expert Opinion on Pharmacotherapy. [DOI: 10.1080/14656566.2022.2054327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Bader SM, Cooney JP, Pellegrini M, Doerflinger M. Programmed cell death: the pathways to severe COVID-19? Biochem J 2022;479:609-28. [PMID: 35244141 DOI: 10.1042/BCJ20210602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
93 Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, Wang Y, Fu C, Jiang Y, He C, Wei Q. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther 2022;7:78. [PMID: 35273164 DOI: 10.1038/s41392-022-00925-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 29.0] [Reference Citation Analysis]
94 Ammirati E, Bizzi E, Veronese G, Groh M, Van de Heyning CM, Lehtonen J, Pineton de Chambrun M, Cereda A, Picchi C, Trotta L, Moslehi JJ, Brucato A. Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. Front Med 2022;9:838564. [DOI: 10.3389/fmed.2022.838564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Narayan P, Trikantzopoulos E, Mezzaroma E, Mauro AG, Vohra H, Abbate A, Toldo S. The interleukin-1 receptor type I promotes the development of aging-associated cardiomyopathy in mice. Cytokine 2022;151:155811. [DOI: 10.1016/j.cyto.2022.155811] [Reference Citation Analysis]
96 Siripanthong B, Asatryan B, Hanff TC, Chatha SR, Khanji MY, Ricci F, Muser D, Ferrari VA, Nazarian S, Santangeli P, Deo R, Cooper LT Jr, Mohiddin SA, Chahal CAA. The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury. JACC Basic Transl Sci 2022;7:294-308. [PMID: 35165665 DOI: 10.1016/j.jacbts.2021.10.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
97 Lin L, Chen Y, Li Q, Xu G, Ding K, Ren L, Shi W, Wang Y, Li Z, Dai W, Wei Z, Yang Y, Bai Z, Xiao X. Isoxanthohumol, a component of Sophora flavescens, promotes the activation of the NLRP3 inflammasome and induces idiosyncratic hepatotoxicity. J Ethnopharmacol 2022;285:114796. [PMID: 34740771 DOI: 10.1016/j.jep.2021.114796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
98 Shao G. Integrated RNA gene expression analysis identified potential immune-related biomarkers and RNA regulatory pathways of acute myocardial infarction. PLoS ONE 2022;17:e0264362. [DOI: 10.1371/journal.pone.0264362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Su XL, Wang SH, Komal S, Cui LG, Ni RC, Zhang LR, Han SN. The caspase-1 inhibitor VX765 upregulates connexin 43 expression and improves cell-cell communication after myocardial infarction via suppressing the IL-1β/p38 MAPK pathway. Acta Pharmacol Sin 2022. [PMID: 35132192 DOI: 10.1038/s41401-021-00845-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Bonaventura A, Vecchié A, Dagna L, Tangianu F, Abbate A, Dentali F. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. Inflamm Res 2022. [PMID: 35113170 DOI: 10.1007/s00011-022-01540-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
101 Samaja M, Pagliaro P. Long and narrow road to win over myocardial ischemia-reperfusion injury. Trends in Cardiovascular Medicine 2022. [DOI: 10.1016/j.tcm.2022.02.013] [Reference Citation Analysis]
102 Braunlin E, Abrahante JE, Mcelmurry R, Evans M, Smith M, Seelig D, O'sullivan MG, Tolar J, Whitley CB, Mcivor RS. Contribution of the innate and adaptive immune systems to aortic dilation in murine mucopolysaccharidosis type I. Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.01.104] [Reference Citation Analysis]
103 Kelk P, Moghbel NS, Hirschfeld J, Johansson A. Aggregatibacter actinomycetemcomitans Leukotoxin Activates the NLRP3 Inflammasome and Cell-to-Cell Communication. Pathogens 2022;11:159. [DOI: 10.3390/pathogens11020159] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
104 Sheu J, Chai H, Chiang JY, Sung P, Chen Y, Yip H. Cellular Prion Protein Is Essential for Myocardial Regeneration but Not the Recovery of Left Ventricular Function from Apical Ballooning. Biomedicines 2022;10:167. [DOI: 10.3390/biomedicines10010167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Jiang K, Tu Z, Chen K, Xu Y, Chen F, Xu S, Shi T, Qian J, Shen L, Hwa J, Wang D, Xiang Y. Gasdermin D inhibition confers antineutrophil-mediated cardioprotection in acute myocardial infarction. J Clin Invest 2022;132:e151268. [PMID: 34752417 DOI: 10.1172/JCI151268] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
106 Cavender MA, O'Donoghue ML, Abbate A, Aylward P, Fox KA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DA. Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. Am Heart J 2022;243:147-57. [PMID: 34508693 DOI: 10.1016/j.ahj.2021.08.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
107 Li N, Dobrev D. Cardiac Inflammasome and Arrhythmia. Cardiovascular Signaling in Health and Disease 2022. [DOI: 10.1007/978-3-031-08309-9_9] [Reference Citation Analysis]
108 Liu X, Li M, Chen Z, Yu Y, Shi H, Yu Y, Wang Y, Chen R, Ge J. Mitochondrial calpain-1 activates NLRP3 inflammasome by cleaving ATP5A1 and inducing mitochondrial ROS in CVB3-induced myocarditis. Basic Res Cardiol 2022;117:40. [PMID: 35997820 DOI: 10.1007/s00395-022-00948-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
109 Zhang S, Zhou J, Wu W, Zhu Y, Liu X. The Role of Bile Acids in Cardiovascular Diseases: from Mechanisms to Clinical Implications. Aging and disease 2022. [DOI: 10.14336/ad.2022.0817] [Reference Citation Analysis]
110 Klein GL. Is calcium a link between inflammatory bone resorption and heart disease? Elife 2022;11. [PMID: 36580074 DOI: 10.7554/eLife.83841] [Reference Citation Analysis]
111 Wang Y, Jiang H, Hu X, Fu W. Bone marrow NLRP3 inflammasome-IL-1β signal regulates post-myocardial infarction megakaryocyte development and platelet production. Biochem Biophys Res Commun 2021;585:96-102. [PMID: 34801938 DOI: 10.1016/j.bbrc.2021.11.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Mezzaroma E, Abbate A, Toldo S. The inflammasome in heart failure. Curr Opin Physiol 2021;19:105-12. [PMID: 34917871 DOI: 10.1016/j.cophys.2020.09.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
113 Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, Van Tassell BW, Abbate A. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther 2021;236:108053. [PMID: 34906598 DOI: 10.1016/j.pharmthera.2021.108053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
114 Gu P, Hui X, Zheng Q, Gao Y, Jin L, Jiang W, Zhou C, Liu T, Huang Y, Liu Q, Nie T, Wang Y, Wang Y, Zhao J, Xu A. Mitochondrial uncoupling protein 1 antagonizes atherosclerosis by blocking NLRP3 inflammasome-dependent interleukin-1β production. Sci Adv 2021;7:eabl4024. [PMID: 34878840 DOI: 10.1126/sciadv.abl4024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
115 Vilela EM, Fontes-Carvalho R. Inflammation and ischemic heart disease: The next therapeutic target? Rev Port Cardiol (Engl Ed) 2021;40:785-96. [PMID: 34857118 DOI: 10.1016/j.repce.2021.10.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
116 Ren FF, Xie ZY, Jiang YN, Guan X, Chen QY, Lai TF, Li L. Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin 2021. [PMID: 34853445 DOI: 10.1038/s41401-021-00805-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
117 Amin S, Aktar S, Rahman MM, Hassan Chowdhury MM. NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity. Microbes Infect 2021;:104913. [PMID: 34838941 DOI: 10.1016/j.micinf.2021.104913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
118 Holzknecht M, Tiller C, Reindl M, Lechner I, Fink P, Lunger P, Mayr A, Henninger B, Brenner C, Klug G, Bauer A, Metzler B, Reinstadler SJ. Association of C-Reactive Protein Velocity with Early Left Ventricular Dysfunction in Patients with First ST-Elevation Myocardial Infarction. J Clin Med 2021;10:5494. [PMID: 34884196 DOI: 10.3390/jcm10235494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
119 Zhang KZ, Shen XY, Wang M, Wang L, Sun HX, Li XZ, Huang JJ, Li XQ, Wu C, Zhao C, Liu JL, Lu X, Gao W. Retinol-Binding Protein 4 Promotes Cardiac Injury After Myocardial Infarction Via Inducing Cardiomyocyte Pyroptosis Through an Interaction With NLRP3. J Am Heart Assoc 2021;10:e022011. [PMID: 34726071 DOI: 10.1161/JAHA.121.022011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
120 Wu J, Dong E, Zhang Y, Xiao H. The Role of the Inflammasome in Heart Failure. Front Physiol 2021;12:709703. [PMID: 34776995 DOI: 10.3389/fphys.2021.709703] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
121 Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, Silva-Pereira C, Albino-Teixeira A, Sousa T. Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. Front Physiol 2021;12:746494. [PMID: 34707513 DOI: 10.3389/fphys.2021.746494] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
122 Ma J, Liu X, Qiao L, Meng L, Xu X, Xue F, Cheng C, Han Z, Lu Y, Zhang W, Bu P, Zhang M, An G, Lu H, Ni M, Zhang C, Zhang Y. Association Between Stent Implantation and Progression of Nontarget Lesions in a Rabbit Model of Atherosclerosis. Circ Cardiovasc Interv 2021;14:e010764. [PMID: 34674554 DOI: 10.1161/CIRCINTERVENTIONS.121.010764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Naviglio S, Zanella G, Verzegnassi F, Kiren V, Giurici N, Sieni E, Coniglio ML, Valencic E, Tommasini A, Rabusin M. IL-1 blockade with anakinra for severe inflammatory symptoms during chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2021;:e29404. [PMID: 34626457 DOI: 10.1002/pbc.29404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Abbate A, Wohlford GF, Del Buono MG, Chiabrando JG, Markley R, Turlington J, Kadariya D, Trankle CR, Biondi-Zoccai G, Lipinski MJ, Van Tassell BW. Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother 2021:pvab075. [PMID: 34617567 DOI: 10.1093/ehjcvp/pvab075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
125 Chen W, Xing J, Liu X, Wang S, Xing D. The role and transformative potential of IL-19 in atherosclerosis. Cytokine Growth Factor Rev 2021;62:70-82. [PMID: 34600839 DOI: 10.1016/j.cytogfr.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Sawada H, Daugherty A, Lu HS. From unbiased transcriptomics to understanding the molecular basis of atherosclerosis. Curr Opin Lipidol 2021;32:328-9. [PMID: 34472541 DOI: 10.1097/MOL.0000000000000773] [Reference Citation Analysis]
127 Vecchié A, Del Buono MG, Chiabrando GJ, Dentali F, Abbate A, Bonaventura A. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. Curr Cardiol Rep 2021;23:157. [PMID: 34599390 DOI: 10.1007/s11886-021-01589-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
128 Bartlett B, Ludewick HP, Lee S, Verma S, Francis RJ, Dwivedi G. Imaging Inflammation in Patients and Animals: Focus on PET Imaging the Vulnerable Plaque. Cells 2021;10:2573. [PMID: 34685553 DOI: 10.3390/cells10102573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
129 Ma S, Feng J, Lin X, Liu J, Tang Y, Nie S, Gong J, Wang L. Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy. Oxid Med Cell Longev 2021;2021:5546867. [PMID: 34567409 DOI: 10.1155/2021/5546867] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
130 Chammas J, Delaney D, Chabaytah N, Abdulkarim S, Schwertani A. COVID-19 and the cardiovascular system: insights into effects and treatments. Can J Physiol Pharmacol 2021;99:1119-27. [PMID: 34546123 DOI: 10.1139/cjpp-2021-0093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Schunk SJ, Triem S, Schmit D, Zewinger S, Sarakpi T, Becker E, Hütter G, Wrublewsky S, Küting F, Hohl M, Alansary D, Prates Roma L, Lipp P, Möllmann J, Lehrke M, Laschke MW, Menger MD, Kramann R, Boor P, Jahnen-Dechent W, März W, Böhm M, Laufs U, Niemeyer BA, Fliser D, Ampofo E, Speer T. Interleukin-1α Is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. Circulation 2021;144:893-908. [PMID: 34192892 DOI: 10.1161/CIRCULATIONAHA.121.053547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
132 Martí-carvajal AJ, De Sanctis JB, Dayer M, Martí-amarista CE, Alegría E, Monge Martín D, Abd El Aziz M, Correa-pérez A, Nicola S, Parise Vasco JM. Interleukin-receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases. Cochrane Database of Systematic Reviews 2021;2021. [DOI: 10.1002/14651858.cd014741] [Reference Citation Analysis]
133 Wu D, Ai L, Sun Y, Yang B, Chen S, Wang Q, Kuang H. Role of NLRP3 Inflammasome in Lupus Nephritis and Therapeutic Targeting by Phytochemicals. Front Pharmacol 2021;12:621300. [PMID: 34489689 DOI: 10.3389/fphar.2021.621300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
134 Balanescu S, Barbu E, Georgescu C, Popescu AC. NLRP3 Inflammasome in Cardiovascular Disease: David's Stone against Goliath? Romanian Journal of Cardiology 2021;31:517-527. [DOI: 10.47803/rjc.2021.31.3.517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Kumrungsee T, Peipei Zhang, Yanaka N, Suda T, Kato N. Emerging cardioprotective mechanisms of vitamin B6: a narrative review. Eur J Nutr 2021. [PMID: 34436643 DOI: 10.1007/s00394-021-02665-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
136 Vaidya K, Tucker B, Patel S, Ng MKC. Acute Coronary Syndromes (ACS)-Unravelling Biology to Identify New Therapies-The Microcirculation as a Frontier for New Therapies in ACS. Cells 2021;10:2188. [PMID: 34571836 DOI: 10.3390/cells10092188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Dimai S, Semmler L, Prabhu A, Stachelscheid H, Huettemeister J, Klaucke SC, Lacour P, Blaschke F, Kruse J, Parwani A, Boldt LH, Bullinger L, Pieske BM, Heinzel FR, Hohendanner F. COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab. PLoS One 2021;16:e0255976. [PMID: 34411149 DOI: 10.1371/journal.pone.0255976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
138 Feng YH, Li LF, Zhang Q, Zhang JH, Huang Y, Lv YL, Jia JZ, Zhang D, Hu JY, Huang YS. Microtubule associated protein 4 (MAP4) phosphorylation reduces cardiac microvascular density through NLRP3-related pyroptosis. Cell Death Discov 2021;7:213. [PMID: 34381021 DOI: 10.1038/s41420-021-00606-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
139 Varghese B, Feldman DI, Chew C, Valilis E, Blumenthal RS, Sharma G, Calkins H. Inflammation, atrial fibrillation, and the potential role for colchicine therapy. Heart Rhythm O2 2021;2:298-303. [PMID: 34337581 DOI: 10.1016/j.hroo.2021.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
140 Fraccarollo D, Neuser J, Möller J, Riehle C, Galuppo P, Bauersachs J. Expansion of CD10neg neutrophils and CD14+HLA-DRneg/low monocytes driving proinflammatory responses in patients with acute myocardial infarction. Elife 2021;10:e66808. [PMID: 34289931 DOI: 10.7554/eLife.66808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
141 Liu Z, Liu H, Deng Q, Sun C, He W, Zheng W, Tang R, Li W, Xie Q. Association Between Dietary Inflammatory Index and Heart Failure: Results From NHANES (1999-2018). Front Cardiovasc Med 2021;8:702489. [PMID: 34307508 DOI: 10.3389/fcvm.2021.702489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
142 Li Y, Huang H, Liu B, Zhang Y, Pan X, Yu XY, Shen Z, Song YH. Inflammasomes as therapeutic targets in human diseases. Signal Transduct Target Ther 2021;6:247. [PMID: 34210954 DOI: 10.1038/s41392-021-00650-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 16.5] [Reference Citation Analysis]
143 Gastaldi S, Boscaro V, Gianquinto E, Sandall CF, Giorgis M, Marini E, Blua F, Gallicchio M, Spyrakis F, MacDonald JA, Bertinaria M. Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. Molecules 2021;26:3975. [PMID: 34209843 DOI: 10.3390/molecules26133975] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
144 Chavkin NW, Sano S, Wang Y, Oshima K, Ogawa H, Horitani K, Sano M, MacLauchlan S, Nelson A, Setia K, Vippa T, Watanabe Y, Saucerman JJ, Hirschi KK, Gokce N, Walsh K. The Cell Surface Receptors Ror1/2 Control Cardiac Myofibroblast Differentiation. J Am Heart Assoc 2021;10:e019904. [PMID: 34155901 DOI: 10.1161/JAHA.120.019904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
145 Gavini MP, Mahmood A, Belenchia AM, Beauparlant P, Kumar SA, Ardhanari S, DeMarco VG, Pulakat L. Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4. Front Pharmacol 2021;12:693167. [PMID: 34220518 DOI: 10.3389/fphar.2021.693167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
146 Zhao N, Di B, Xu LL. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev 2021:S1359-6101(21)00054-X. [PMID: 34183243 DOI: 10.1016/j.cytogfr.2021.06.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 20.0] [Reference Citation Analysis]
147 Aliaga J, Bonaventura A, Mezzaroma E, Dhakal Y, Mauro AG, Abbate A, Toldo S. Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177® (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction. Molecules 2021;26:3534. [PMID: 34207886 DOI: 10.3390/molecules26123534] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
148 Holmes MV, Richardson TG, Ference BA, Davies NM, Davey Smith G. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat Rev Cardiol 2021;18:435-53. [PMID: 33707768 DOI: 10.1038/s41569-020-00493-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 25.0] [Reference Citation Analysis]
149 Zhang J, Ogbu SC, Musich PR, Thewke DP, Yao Z, Jiang Y. The Contribution of Endothelial-Mesenchymal Transition to Atherosclerosis. IJTM 2021;1:39-54. [DOI: 10.3390/ijtm1010004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Münzer P, Negro R, Fukui S, di Meglio L, Aymonnier K, Chu L, Cherpokova D, Gutch S, Sorvillo N, Shi L, Magupalli VG, Weber ANR, Scharf RE, Waterman CM, Wu H, Wagner DD. NLRP3 Inflammasome Assembly in Neutrophils Is Supported by PAD4 and Promotes NETosis Under Sterile Conditions. Front Immunol 2021;12:683803. [PMID: 34122445 DOI: 10.3389/fimmu.2021.683803] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
151 Alfaidi M, Scott ML, Orr AW. Sinner or Saint?: Nck Adaptor Proteins in Vascular Biology. Front Cell Dev Biol 2021;9:688388. [PMID: 34124074 DOI: 10.3389/fcell.2021.688388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Fragoulis GE, Soulaidopoulos S, Sfikakis PP, Dimitroulas T, D Kitas G. Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction. J Inflamm Res 2021;14:1915-31. [PMID: 34017189 DOI: 10.2147/JIR.S282691] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
153 Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov 2021;20:589-610. [PMID: 33976384 DOI: 10.1038/s41573-021-00198-1] [Cited by in Crossref: 133] [Cited by in F6Publishing: 154] [Article Influence: 66.5] [Reference Citation Analysis]
154 Wang D, Zhang Y, Xu X, Wu J, Peng Y, Li J, Luo R, Huang L, Liu L, Yu S, Zhang N, Lu B, Zhao K. YAP promotes the activation of NLRP3 inflammasome via blocking K27-linked polyubiquitination of NLRP3. Nat Commun 2021;12:2674. [PMID: 33976226 DOI: 10.1038/s41467-021-22987-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
155 Sheriff L, Lalor PF. The Impact of the NLRP3 Pathway in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease. Livers 2021;1:68-81. [DOI: 10.3390/livers1020007] [Reference Citation Analysis]
156 Li Z, Zhao H, Wang J. Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities. Front Cardiovasc Med 2021;8:650278. [PMID: 34026868 DOI: 10.3389/fcvm.2021.650278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
157 Samsonov M, Bogin V, Van Tassell BW, Abbate A. Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale. J Transl Med 2021;19:169. [PMID: 33902621 DOI: 10.1186/s12967-021-02828-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Lorenzatti AJ. Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials. Eur Cardiol 2021;16:e15. [PMID: 33976710 DOI: 10.15420/ecr.2020.51] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
159 Libby P. Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond. Cells 2021;10:951. [PMID: 33924019 DOI: 10.3390/cells10040951] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
160 van der Heijden WA, Van de Wijer L, Keramati F, Trypsteen W, Rutsaert S, Horst RT, Jaeger M, Koenen HJ, Stunnenberg HG, Joosten I, Verweij PE, van Lunzen J, Dinarello CA, Joosten LA, Vandekerckhove L, Netea MG, van der Ven AJ, de Mast Q. Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. JCI Insight 2021;6:145928. [PMID: 33630761 DOI: 10.1172/jci.insight.145928] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
161 Bai B, Yang Y, Ji S, Wang S, Peng X, Tian C, Sun RC, Yu T, Chu XM. MicroRNA-302c-3p inhibits endothelial cell pyroptosis via directly targeting NOD-, LRR- and pyrin domain-containing protein 3 in atherosclerosis. J Cell Mol Med 2021;25:4373-86. [PMID: 33783966 DOI: 10.1111/jcmm.16500] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
162 Świątkiewicz I, Magielski P, Kubica J. C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period. Int J Mol Sci 2021;22:3169. [PMID: 33804661 DOI: 10.3390/ijms22063169] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
163 Dabbish AM, Yonis N, Salama M, Essa MM, Qoronfleh MW. Inflammatory pathways and potential therapies for COVID-19: A mini review. Eur J Inflamm 2021;19:205873922110029. [DOI: 10.1177/20587392211002986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
164 Shi J, Guo J, Li Z, Xu B, Miyata M. Importance of NLRP3 Inflammasome in Abdominal Aortic Aneurysms. J Atheroscler Thromb 2021;28:454-66. [PMID: 33678767 DOI: 10.5551/jat.RV17048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
165 Chavkin NW, Sano S, Wang Y, Oshima K, Ogawa H, Horitani K, Sano M, Maclauchlan S, Nelson A, Setia K, Vippa T, Watanabe Y, Saucerman JJ, Hirschi KK, Gokce N, Walsh K. The Cell Surface Receptors Ror1/2 Control Cardiac Myofibroblast Differentiation.. [DOI: 10.1101/2021.03.02.433549] [Reference Citation Analysis]
166 Pearce L, Davidson SM, Yellon DM. Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response. Basic Res Cardiol 2021;116:12. [PMID: 33629195 DOI: 10.1007/s00395-021-00852-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
167 Mauro AG, Bonaventura A, Vecchié A, Mezzaroma E, Carbone S, Narayan P, Potere N, Cannatà A, Paolini JF, Bussani R, Montecucco F, Sinagra G, Van Tassel BW, Abbate A, Toldo S. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC Basic Transl Sci 2021;6:137-50. [PMID: 33665514 DOI: 10.1016/j.jacbts.2020.11.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
168 Mezzaroma E, Abbate A, Toldo S. NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases. Molecules 2021;26:976. [PMID: 33673188 DOI: 10.3390/molecules26040976] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
169 Tuli HS, Sood S, Kaur J, Kumar P, Seth P, Punia S, Yadav P, Sharma AK, Aggarwal D, Sak K. Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. 3 Biotech 2021;11:110. [PMID: 33552835 DOI: 10.1007/s13205-021-02644-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Zhang J, Almoallim HS, Ali Alharbi S, Yang B. Anti-atherosclerotic activity of Betulinic acid loaded polyvinyl alcohol/methylacrylate grafted Lignin polymer in high fat diet induced atherosclerosis model rats. Arabian Journal of Chemistry 2021;14:102934. [DOI: 10.1016/j.arabjc.2020.102934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Huff MW, Rayner KJ. Atherosclerosis. Biochemistry of Lipids, Lipoproteins and Membranes 2021. [DOI: 10.1016/b978-0-12-824048-9.00013-4] [Reference Citation Analysis]
172 Zhao W, Zhao J, Rong J. Pharmacological Modulation of Cardiac Remodeling after Myocardial Infarction. Oxid Med Cell Longev 2020;2020:8815349. [PMID: 33488934 DOI: 10.1155/2020/8815349] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
173 McCarty MF, Iloki Assanga SB, Lewis Luján L, O'Keefe JH, DiNicolantonio JJ. Nutraceutical Strategies for Suppressing NLRP3 Inflammasome Activation: Pertinence to the Management of COVID-19 and Beyond. Nutrients 2020;13:E47. [PMID: 33375692 DOI: 10.3390/nu13010047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
174 Wang H, Jing ZC. Inflammation and cardiovascular diseases. Chronic Dis Transl Med 2020;6:215-8. [PMID: 33336166 DOI: 10.1016/j.cdtm.2020.09.003] [Reference Citation Analysis]
175 Landi L, Ravaglia C, Russo E, Cataleta P, Fusari M, Boschi A, Giannarelli D, Facondini F, Valentini I, Panzini I, Lazzari-Agli L, Bassi P, Marchionni E, Romagnoli R, De Giovanni R, Assirelli M, Baldazzi F, Pieraccini F, Rametta G, Rossi L, Santini L, Valenti I, Cappuzzo F. Blockage of interleukin-1β with canakinumab in patients with Covid-19. Sci Rep 2020;10:21775. [PMID: 33311551 DOI: 10.1038/s41598-020-78492-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
176 Wen J, Chang Y, Huo S, Li W, Huang H, Gao Y, Lin H, Zhang J, Zhang Y, Zuo Y, Cao X, Zhong F. Tanshinone IIA attenuates atherosclerosis via inhibiting NLRP3 inflammasome activation. Aging (Albany NY) 2020;13:910-32. [PMID: 33290264 DOI: 10.18632/aging.202202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
177 Dehghani T, Panitch A. Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle. Open Biol 2020;10:200161. [PMID: 33050789 DOI: 10.1098/rsob.200161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
178 Dixon DL. Introducing Emerging Concepts in Pharmacotherapeutics. J Cardiovasc Pharmacol 2020;76:372-3. [PMID: 33027193 DOI: 10.1097/FJC.0000000000000904] [Reference Citation Analysis]
179 Kirkman DL, Bohmke N, Billingsley HE, Carbone S. Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction. Front Endocrinol (Lausanne) 2020;11:558271. [PMID: 33117276 DOI: 10.3389/fendo.2020.558271] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
180 Chen M, Li X, Wang S, Yu L, Tang J, Zhou S. The Role of Cardiac Macrophage and Cytokines on Ventricular Arrhythmias. Front Physiol 2020;11:1113. [PMID: 33071805 DOI: 10.3389/fphys.2020.01113] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
181 Fraccarollo D, Neuser J, Möller J, Riehle C, Galuppo P, Bauersachs J. Expansion of CD10neg neutrophils and CD14+HLA-DRneg/low monocytes driving proinflammatory responses in patients with acute myocardial infarction.. [DOI: 10.1101/2020.09.21.306118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
182 Hanna A, Frangogiannis NG. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. Cardiovasc Drugs Ther 2020;34:849-63. [PMID: 32902739 DOI: 10.1007/s10557-020-07071-0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 21.3] [Reference Citation Analysis]
183 Bertocchi I, Foglietta F, Collotta D, Eva C, Brancaleone V, Thiemermann C, Collino M. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. Br J Pharmacol 2020;177:4921-30. [PMID: 32776354 DOI: 10.1111/bph.15229] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
184 Buckley LF, Wohlford GF, Ting C, Alahmed A, Van Tassell BW, Abbate A, Devlin JW, Libby P. Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. Crit Care Explor 2020;2:e0178. [PMID: 32832913 DOI: 10.1097/CCE.0000000000000178] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
185 Liu H, Liu X, Zhuang H, Fan H, Zhu D, Xu Y, He P, Liu J, Feng D. Mitochondrial Contact Sites in Inflammation-Induced Cardiovascular Disease. Front Cell Dev Biol 2020;8:692. [PMID: 32903766 DOI: 10.3389/fcell.2020.00692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
186 Kadosh BS, Garshick MS, Gaztanaga J, Moore KJ, Newman JD, Pillinger M, Ramasamy R, Reynolds HR, Shah B, Hochman J, Fishman GI, Katz SD. COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2020;40:2045-53. [PMID: 32687400 DOI: 10.1161/ATVBAHA.120.314513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
187 Caseley EA, Poulter JA, Rodrigues F, McDermott MF; Immunome Project Consortium for Autoinflammatory Disorders (ImmunAID). Inflammasome inhibition under physiological and pharmacological conditions. Genes Immun 2020;21:211-23. [PMID: 32681062 DOI: 10.1038/s41435-020-0104-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
188 Iannaccone G, Scacciavillani R, Del Buono MG, Camilli M, Ronco C, Lavie CJ, Abbate A, Crea F, Massetti M, Aspromonte N. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Cardiorenal Med 2020;10:277-87. [PMID: 32599589 DOI: 10.1159/000509483] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 15.7] [Reference Citation Analysis]
189 Keshavarz-Bahaghighat H, Darwesh AM, Sosnowski DK, Seubert JM. Mitochondrial Dysfunction and Inflammaging in Heart Failure: Novel Roles of CYP-Derived Epoxylipids. Cells 2020;9:E1565. [PMID: 32604981 DOI: 10.3390/cells9071565] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
190 Baragetti A, Catapano AL, Magni P. Multifactorial Activation of NLRP3 Inflammasome: Relevance for a Precision Approach to Atherosclerotic Cardiovascular Risk and Disease. Int J Mol Sci 2020;21:E4459. [PMID: 32585928 DOI: 10.3390/ijms21124459] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
191 Ucciferri C, Auricchio A, Di Nicola M, Potere N, Abbate A, Cipollone F, Vecchiet J, Falasca K. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;. [PMID: 32835251 DOI: 10.1016/s2665-9913(20)30167-3] [Cited by in Crossref: 85] [Cited by in F6Publishing: 89] [Article Influence: 28.3] [Reference Citation Analysis]
192 Libby P, Bornfeldt KE. How Far We Have Come, How Far We Have Yet to Go in Atherosclerosis Research. Circ Res 2020;126:1107-11. [PMID: 32324500 DOI: 10.1161/CIRCRESAHA.120.316994] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]